Browse

A standard chemotherapy drug loaded in nanoparticles has been able to penetrate the blood-brain barrier when administered shortly after resection of the tumor, new research has suggested.

Biogen's business development team may have been busy in recent years, but CEO Christopher Viehbacher is easing off the acquisitions for a while.

Novo Nordisk’s attempt to dismiss a lawsuit about its CagriSema readout has failed, with the judge ruling that parts of the investors’ argument were strong enough for the case to proceed.